A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Clinical trial NCT06736561 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06736561
Sponsor: Harbin Medical University
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

ALK Positive Ensartinib NSCLC Neoadjuvant Therapy

Start date: 2025-01-01
Primary completion: 2027-12-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.